Drug Trial Radar · NCT07615179
Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,545
Actual
Start
Feb 17, 2025
Primary completion
Sep 30, 2025
Study completion May 30, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.
Conditions
- Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions
AlirocumabDrug
The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.
Comparator: No PCSK9i Therapy (either mAb or siRNA)Drug
The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortalityTime frame: From index up to 5 years follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi
Bridgewater, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.